On May 28, 2025, Karyopharm Therapeutics Inc. stockholders approved an increase of 450,000 shares available under the company's 2022 Equity Incentive Plan, alongside the election of new directors and ratification of the accounting firm. The overall sentiment is positive for the company as these changes support growth and governance.